Internal Reference Number: FOI_9270
Date Request Received: 06/03/2026 00:00:00
Date Request Replied To: 23/03/2026 00:00:00
This response was sent via: By Email
Request Summary: Ophthalmology Use of Kenalog (Triamcinolone)
Request Category: Companies
| Question Number 1: I am submitting a request under the Freedom of Information Act 2000. Please provide the following information relating specifically to the use of Kenalog (triamcinolone) within your Ophthalmology department: The number of Kenalog administrations carried out in Ophthalmology for each of the last three financial years. | |
| Answer To Question 1: We use 1 vial/patient so: 2023 15 vials 2024 50 vials 2025 20 vials 2026 no usage due to discontinuation of licensed product | |
| Question Number 2: A breakdown of the clinical indications recorded for Kenalog use in Ophthalmology (e.g., uveitis, macular oedema, post operative inflammation), if available. | |
| Answer To Question 2: The only 3 are: Subconjunctival/subtenon injection in severe uveitis During vitrectomy in complex cataract surgery To manage post-op inflammation in patients who cannot manage post-operative drops with cataract surgery | |
| Question Number 3: Any local guidelines, protocols, or clinical policies governing the use of Kenalog in Ophthalmology. | |
| Answer To Question 3: The only local guidelines we have for Ophthalmology, referencing triamcinolone is a section in the Emergency Ophthalmology Clinic Guidelines 1 which is found in: SA国际传媒 > Hospital Guidelines > Adult Surgery > Ophthalmology > Juniors Drs Handbook On EOLAS: https://app.eolasmedical.com/auto-login/EOLAS%23ORG%23staging-salisbury-nhs-foundation-trust%231120b4c7-8856-4520-934a-f2778c95fc7a%23860230f5-00eb-4248-8db4-c71d458f6f81 And states: Condition - Intermediate Uveitis Standard management at initial visit - 路 Hourly Topical steroids 路 If VA significantly low- Periocular corticosteroids (posterior sub-tenon route or retroseptally) methylprednisolone (40 mg) or triamcinolone acetonide (20 mg) is given either through the through the lower lid 路 Investigations- FBC, ESR, CRP, Serum ACE level, chest x-ray, Syphilis serology, lyme serology, ANA, ANCA. Further investigations as per clinical and systemic features Remember masquerades-Rule out malignancy Standard disposal (with appropriate safety-netting) - d/w RA/Cons In-charge Uveitis Clinic-2-6 weeks depending upon severity --------- Kenalog is no longer kept by SFT ophthalmology department as it has been withdrawn from the UK market and alternative treatment options are now used in our service. | |
| Question Number 4: Any recorded adverse events, Datix reports, or safety concerns relating to Kenalog use in Ophthalmology during the same period. | |
| Answer To Question 4: None | |
| Question Number 5: The number of vials issued by pharmacy to Ophthalmology for Kenalog in each of the last three financial years, if held. | |
| Answer To Question 5: To the best of our knowledge these issues can be directly related to ophthalmology use. 2023 15 vials 2024 50 vials 2025 20 vials 2026 no usage due to discontinuation of licensed product | |
| Question Number 6: Whether Kenalog (triamcinolone) is listed on the Trust鈥檚 formulary for Ophthalmology, and if so, any restrictions or criteria for its use. | |
| Answer To Question 6: No. Triamcinolone inj is non-formulary in BSW | |
| Question Number 7: As Kenalog has been withdrawn from the UK market, please provide any recorded information, internal communications, policies, or decisions relating to: 鈥� whether the Ophthalmology department is continuing to use existing stock, 鈥� any plans or decisions to discontinue its use, and 鈥� any identified or recommended alternative treatments. | |
| Answer To Question 7: SFT do not have any remaining licensed product stock.聽 Ophthalmology have considered and utilise alternative treatments available, as advised in the MSN.聽 | |
| To return to the list of all the FOI requests please click here |
Our staff at SA国际传媒 Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
